Relay Therapeutics, Inc. (RLAY)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
18.73 USD
-1.28
(-6.373%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 18.45 -0.28 (-0.280%) ⇩ (July 13, 2026, 7:38 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:48 a.m. EDT
The investment case for Relay Therapeutics is currently broken by a catastrophic multi-year decline. The stock has lost nearly 90% of its value over the last five years, with every single year showing negative returns. This is not a temporary correction; it is a structural implosion where the market has repeatedly rejected the business model. Fundamentally, the company is generating massive losses, burning through cash, and shrinking revenue by over 60%. While the balance sheet remains technically liquid due to cash reserves, the relentless sell-off suggests investors believe the pipeline cannot generate the returns needed to sustain operations without massive dilution or a miracle. The recent inclusion in a growth index failed to spark a sustainable recovery, and insider selling by executives reinforces a lack of confidence in the near-term outlook. With no dividend to provide income and a trajectory of continuous deterioration, this is a security to avoid entirely. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.125107 |
| AutoETS | 0.125107 |
| MSTL | 0.127060 |
| AutoTheta | 0.130849 |
| MSTL_115 | 0.142953 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.112 |
| Excess Kurtosis | -0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.916 |
| Revenue per Share | 0.061 |
| Market Cap | 4,082,022,400 |
| Forward P/E | -11.33 |
| Beta | 1.68 |
| Website | https://www.relaytx.com |
As of July 11, 2026, 4:48 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 7, 8, 12, 13) and significant volume in new put flows. Conversely, call activity is concentrated near the money or slightly out-of-the-money, with very low open interest on deep in-the-money strikes, indicating a lack of conviction in a major recovery. Implied volatility is significantly elevated on the downside strikes compared to the upside, reflecting a market pricing in a high probability of further decline rather than a speculative rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.619382 |
| Address1 | 60 Hampshire Street |
| All Time High | 64.37 |
| All Time Low | 1.775 |
| Ask | 23.71 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 4,934,780 |
| Average Daily Volume3 Month | 4,259,822 |
| Average Volume | 4,259,822 |
| Average Volume10Days | 4,934,780 |
| Beta | 1.682 |
| Bid | 13.97 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 3.394 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.73 |
| Current Ratio | 22.132 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 19.75 |
| Day Low | 18.35 |
| Debt To Equity | 4.916 |
| Display Name | Relay Therapeutics |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -293,606,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.143 |
| Enterprise To Revenue | 278.935 |
| Enterprise Value | 2,977,910,784 |
| Eps Current Year | -1.53253 |
| Eps Forward | -1.65358 |
| Eps Trailing Twelve Months | -1.56 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.1103 |
| Fifty Day Average Change | 3.6196995 |
| Fifty Day Average Change Percent | 0.2395518 |
| Fifty Two Week Change Percent | 461.9382 |
| Fifty Two Week High | 20.79 |
| Fifty Two Week High Change | -2.0600014 |
| Fifty Two Week High Change Percent | -0.09908616 |
| Fifty Two Week Low | 3.025 |
| Fifty Two Week Low Change | 15.705 |
| Fifty Two Week Low Change Percent | 5.1917353 |
| Fifty Two Week Range | 3.025 - 20.79 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,906,200,000 |
| Float Shares | 136,139,213 |
| Forward Eps | -1.65358 |
| Forward P E | -11.32694 |
| Free Cashflow | -121,180,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 193 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -245,584,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.013710001 |
| Held Percent Institutions | 0.87081003 |
| Implied Shares Outstanding | 217,940,332 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-16 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Relay Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,082,022,400 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_384027698 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -272,704,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,358,806,640 |
| Number Of Analyst Opinions | 12 |
| Open | 19.542 |
| Operating Cashflow | -213,356,992 |
| Operating Margins | -26.19667 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 370 8837 |
| Post Market Change | -0.27999878 |
| Post Market Change Percent | -1.4949214 |
| Post Market Price | 18.45 |
| Post Market Time | 1,783,985,935 |
| Previous Close | 20.005 |
| Price Eps Current Year | -12.221621 |
| Price Hint | 2 |
| Price To Book | 5.518562 |
| Price To Sales Trailing12 Months | 382.35504 |
| Profit Margins | 0.0 |
| Quick Ratio | 21.581 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.23077 |
| Region | US |
| Regular Market Change | -1.275 |
| Regular Market Change Percent | -6.3734 |
| Regular Market Day High | 19.75 |
| Regular Market Day Low | 18.35 |
| Regular Market Day Range | 18.35 - 19.75 |
| Regular Market Open | 19.542 |
| Regular Market Previous Close | 20.005 |
| Regular Market Price | 18.73 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,313,049 |
| Return On Assets | -0.24722 |
| Return On Equity | -0.40008 |
| Revenue Growth | -0.609 |
| Revenue Per Share | 0.061 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 217,940,332 |
| Shares Percent Shares Out | 0.1975 |
| Shares Short | 43,041,464 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 34,389,240 |
| Short Name | Relay Therapeutics, Inc. |
| Short Percent Of Float | 0.23020001 |
| Short Ratio | 8.72 |
| Source Interval | 15 |
| State | MA |
| Symbol | RLAY |
| Target High Price | 32.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 25.08333 |
| Target Median Price | 26.0 |
| Total Cash | 642,065,024 |
| Total Cash Per Share | 3.351 |
| Total Debt | 31,567,000 |
| Total Revenue | 10,676,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.334125 |
| Two Hundred Day Average Change | 8.395875 |
| Two Hundred Day Average Change Percent | 0.8124418 |
| Type Disp | Equity |
| Volume | 2,313,049 |
| Website | https://www.relaytx.com |
| Zip | 2,139 |